Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC
Status:
Completed
Trial end date:
2020-05-26
Target enrollment:
Participant gender:
Summary
The aim of the trial is to evaluate the clinical benefit (efficacy, safety, preservation of
autonomy) of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or
metastatic head and neck squamous cell carcinoma in patients over 70 years without frailty
(after geriatric assessment).